Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia

H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 15, 2024 • 10:30am EDT

Canaccord Genuity 44th Annual Growth Conference

Aug 14, 2024 • 9:00am EDT